Heipo F.C. Tablets 300mg "EVEREST"

Heipo F.C. Tablets 300mg "EVEREST"

CARDIOVASCULAR SYSTEM Agents acting on the renin-angiotensin system

Irbesartan ……300mg

Package 14's x 70PTP/ Box

Essential Hypertension

Type 2 Diabetes

Diabetic Nephropathy

Signa (Sig.)

It is generally recommended that the starting dose and maintenance dose be once daily, 150 mg each time, with meals or on an empty stomach. Usually Irbesartan once daily, 150mg per time provides a better blood pressure control (within 24 hours) than 75mg. However, 75 mg can be considered as the initial treatment, especially for hemodialysis patients, and for those older than 75 years. If you take it once a day, 150mg still does not adequately control your blood pressure, you can increase the dose to 300mg, or add other antihypertensive agents. The addition of diuretics, such as hydrochlorothiazide, has been shown to have an additive effect with Irbesartan.

Patients with type 2 diabetes who have hypertension, when treating kidney disease, take 150mg once a day as the initial treatment. It is recommended that the maintenance dose be gradually increased to 300mg once a day to treat kidney disease.

The protective effect of Irbesartan on the kidneys of patients with type 2 diabetes who have hypertension has been confirmed by clinical trials. In these trials, Irbesartan used other hypotensive agents to achieve a predetermined blood pressure value based on medical needs.

Renal insufficiency: Patients with renal insufficiency do not need to adjust the dose of Irbesartan; patients receiving hemodialysis should consider starting treatment at a lower dose (75 mg).

Hepatic insufficiency: Patients with mild to moderate hepatic insufficiency do not need to adjust the dose of Irbesartan. There is currently no clinical experience with Irbesartan for patients with severe hepatic insufficiency.

Elderly patients: When Irbesartan is used in elderly patients over the age of 75, treatment should be considered starting with 75 mg; however, it is usually not necessary for the elderly to adjust the dose.

Children: The safety and efficacy of Irbesartan for children has not been established.

Storage Refer Leaflet
Health Insurance Code AB57864100
DOH Manufacturing No. DOH. Ref. No 057864

Related Products